报告题目：Novel Chiral Ligands Synthesis and Their Applications inPharmaceutical Manufacturing

报告人：郭荣伟博士 (Kanata Chemical Technologies Inc.)

报告时间：4月7日（周二）上午10:00

报告地点：18号楼218室

报告人简介:

郭荣伟博士，加拿大Kanata Chemical Technologies Inc. 首席科学家，研发部门负责人。1991年上海有机化学研究所硕士，2002年香港理工大学博士，2003-2005年，多伦多大学化学系博士后。之后进入加拿大Kanata Chemical Technologies Inc.，先后任研究员，高级研究员，项目经理，2008年起，担任该公司研发部负责人，2013年起成为该公司首席科学家。目前主要从事C=C, C=O以及C=N的不对称氢化方面的研究工作，为活性药物中间体发展新的技术路线。

报告摘要:

Reduction of C=C, C=O and C=N double bond by asymmetric hydrogenation catalyzed with Rhodium, Ruthenium or Iridium complex is an efficient and attractive approach to desired single enantiomer product. The combination of transition metal and chiral ligand provide a wide range of catalysts for asymmetric hydrogenations. In recent decades, the asymmetric hydrogenation of prochiral ketones, olefins and enamines were widely investigated for the preparation of API. Herein, we will report a new process for the preparation of novel chiral aminophosphine ligands (abbreviated P-N Ligands) and their derivatives. These hemilabile P-N ligands contain a combination of hard Lewis base (nitrogen) and soft Lewis base (phosphorous) chelating centers in one molecule which make this kind of ligands potentially advantages in catalytic reactions. In this presentation, we will also report the synthesis of novel chiral diphosphine ligands--Garphos ligands and their applications in the preparation of Atovastatin, Aprepitant, Duloxetin, Montelukast, Pregablin and Sitagliptin. The features of this type ligands are of high activity and enantioselectivity in asymmetric catalytic hydrogenation of C=C, C=O and C=N double bond.

欢迎广大教师和学生参加！

化学工程与技术浙江省重中之重学科